KBP Biosciences   Report issue

For profit Phase 1 Phase 3
Founded: Princeton NJ United States (2007)

Organization Overview

First Clinical Trial
2014
NCT02228733
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

KBP Biosciences | KBP Biosciences Co., Ltd. | KBP Biosciences USA Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

Ocedurenone (9 trials)

Drugs in Phase 1 Trials (3)

itraconazole (sporanox) (1 trial)

kbp-7072 (4 trials)

rifampin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hypertension (Phase 2)

Kidney Diseases (Phase 2)

Liver Diseases (Phase 1)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 4